Sweden· SE-20171103000069
Vyxeos liposomal 44 mg/100 mg Pulver till koncentrat till infusionsvätska, lösning
A medicinal product containing daunorubicin hydrochloride + cytarabine, registered in Sweden by Jazz Pharmaceuticals Ireland Limited.
Checked against Swedish Medical Products Agency (Sweden) on
Informational only — not a medical device.
The record
At a glance
Swedish Medical Products Agency (Sweden)- Active substance
- Daunorubicin Hydrochloride + Cytarabine
- Manufacturer
- Jazz Pharmaceuticals Ireland Limited
- Country
- Sweden (SE)
- ATC code
- —
- Reimbursed
- Not published by this register
- Source register
- Swedish Medical Products Agency (Sweden)
- Last checked
- October 1, 2026
Packs & prices · 1
- se_varunummer20171103000069
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Daunorubicin hydrochloride + cytarabine in 13 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- CzechiaVYXEOS LIPOSOMALJazz Pharmaceuticals Ireland Ltd, Dublin
- SwitzerlandVyxeos liposomal 44 mg/100 mg, Pulver für ein Konzentrat zur Herstellung einer InfusionsdispersionJazz Pharmaceuticals Switzerland GmbH
- FinlandVyxeos liposomalJazz Pharmaceuticals Ireland Limited
- United KingdomVyxeos liposomal 44mg/100mg powder for concentrate for solution for infusion vialsJazz Pharmaceuticals UK Ltd
- IrelandVyxeos liposomal 44 mg/100 mg powder for concentrate for solution for infusionJazz Pharmaceuticals Ireland Limited
- IcelandVyxeos liposomalJazz Pharmaceuticals Ireland Ltd
- NetherlandsVyxeos liposomal 44 mg/100 mg poeder voor concentraat voor oplossing voor infusieJazz Pharmaceuticals Ireland Limited
- NorwayVyxeos liposomalJazz Pharmaceuticals Ireland Limited
Authorised across Europe · EMA
The same active substance is authorised in 3 EEA countries. Names it is sold under:
- Iceland · Vyxeos Liposomal
- Liechtenstein · Vyxeos Liposomal
- Norway · Vyxeos Liposomal
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Swedish Medical Products Agency (Sweden). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/ae6d413f-a1e4-4ef9-9b74-287a0a961812 GET /v1/drugs/ae6d413f-a1e4-4ef9-9b74-287a0a961812?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"source": "lakemedelsverket",
"doc_types": [
"EMA",
"EPAR"
],
"se_npl_id": "20171103000069",
"product_page": "https://www.lakemedelsverket.se/sv/sok-lakemedelsfakta/lakemedel?id=20171103000069",
"product_doc_link": "https://www.ema.europa.eu/en/medicines/human/EPAR/vyxeos-liposomal"
}See everything about daunorubicin hydrochloride + cytarabine.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.